Malik Manal Arshad, Kamran Aleena, Ahsan Dua, Amjad Aafia, Moatter Sara, Noor Amna, Sohaib Asharib, Shaukat Maryam, Masood Waniyah, Hasanain Muhammad, Mahmmoud Fadelallah Eljack Mohammed
Liaquat National Hospital, Karachi, Pakistan.
Jinnah Medical and Dental College, Karachi, Pakistan.
Ann Med Surg (Lond). 2025 May 12;87(6):3673-3681. doi: 10.1097/MS9.0000000000003348. eCollection 2025 Jun.
Tuberculosis (TB), caused by , continues to be a major global health issue, particularly due to its potential to cause severe complications such as tubercular meningitis (TBM), which is a fatal condition that proves difficult to diagnose and treat effectively and often results in poor outcomes, especially in children, due to delayed diagnosis, drug resistance, and limited diagnostic techniques.
This review provides a comprehensive overview of recent advancements in TBM management and treatment. A systematic search was performed across major databases, including PubMed, Google Scholar, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, and the ISRCTN Registry. The search strategy used terms like ("tubercular meningitis" OR "TBM" OR "TB meningitis") AND ("diagnosis" OR "treatment" OR "clinical trials"). Inclusion criteria focused on studies published from January 2014 to September 2024, highlighting novel diagnostics, therapeutic advances, and clinical trials for TBM. Exclusion criteria involved studies unrelated to TBM or older than 10 years.
Diagnostic methods for TBM, such as microbiological and molecular techniques (Fig. 1), vary in sensitivity, with polymerase chain reaction assays being the most sensitive. While anti-TB drugs are available, drug resistance and poor cerebrospinal fluid penetration limit effectiveness. New molecular diagnostics and therapies, including anti-TNF agents, anti-inflammatory drugs, and antibiotics, show promise for improving outcomes.Figure 1.A summary of the diagnosis and management of tuberculosis meningitis.
Despite recent advancements in TBM diagnostics and treatment, substantial challenges remain, particularly in addressing drug resistance and improving drug efficacy in the central nervous system. Continued innovation in molecular diagnostics and treatment approaches is essential to enhance TBM care and mitigate its devastating consequences.
由结核分枝杆菌引起的结核病仍然是一个重大的全球健康问题,特别是因为它有可能导致严重并发症,如结核性脑膜炎(TBM),这是一种致命疾病,难以有效诊断和治疗,由于诊断延迟、耐药性和有限的诊断技术,往往导致不良后果,尤其是在儿童中。
本综述全面概述了结核性脑膜炎管理和治疗的最新进展。在包括PubMed、谷歌学术、ClinicalTrials.gov、世界卫生组织国际临床试验注册平台和ISRCTN注册库在内的主要数据库中进行了系统检索。检索策略使用了诸如(“结核性脑膜炎”或“TBM”或“结核性脑膜炎”)和(“诊断”或“治疗”或“临床试验”)等术语。纳入标准侧重于2014年1月至2024年9月发表的研究,重点是结核性脑膜炎的新型诊断方法、治疗进展和临床试验。排除标准涉及与结核性脑膜炎无关或超过10年的研究。
结核性脑膜炎的诊断方法,如微生物学和分子技术(图1),敏感性各不相同,聚合酶链反应检测是最敏感的。虽然有抗结核药物,但耐药性和脑脊液穿透性差限制了疗效。新的分子诊断和治疗方法,包括抗TNF药物、抗炎药物和抗生素,有望改善治疗结果。图1.结核性脑膜炎的诊断和管理总结。
尽管结核性脑膜炎的诊断和治疗最近取得了进展,但仍然存在重大挑战,特别是在解决耐药性和提高中枢神经系统药物疗效方面。分子诊断和治疗方法的持续创新对于加强结核性脑膜炎护理和减轻其破坏性后果至关重要。